Catalyst Wire Dossier Catalyst Wire Dossier

CGB-500 Topical Ointment (1% tofacitinib)

tofacitinib · CAGE Bio Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGB-500 Topical Ointment (1% tofacitinib), covering 2025-02-13 to 2025-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis [Phase 1, Phase 2]

See pricing